PROVIDENCE – Researchers at Women & Infants Hospital of Rhode Island recently published the results of an investigation into more successful tailoring of therapy for ovarian cancer.
The work comes out of the molecular therapeutic laboratory directed by Dr. Richard G. Moore, MD, of Women & Infants’ Program in Women’s Oncology. Entitled “HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation,” the research was recently published in the international science journal Scientific Reports, a Nature publishing group.
The goal of the study was to investigate the role of the hormone HE4 in modulating an ovarian cancer’s response to hormones and hormonal therapies. HE4 is a biomarker that is elevated in ovarian cancer and is known to play a role in resistance to chemotherapy.?
Moore’s lab will continue to investigate the expression of estrogen receptors in both primary and recurrent ovarian cancers and how that relates to HE4 expression.
